---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-004527"
form_type: "8-K"
ticker: "KLRS"
cik: "0001754068"
company_name: "Kalaris Therapeutics, Inc."
filed_at: "2025-01-10T23:59:59+00:00"
generated_at: "2026-05-28T05:22:11.130960+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.45
calibrated_materiality_score: 0.45
confidence: "high"
source: SEC EDGAR
---

# AlloVir announces 1-for-23 reverse stock split effective Jan 15, 2025

## Summary
- Board approved 1-for-23 reverse stock split; effective 4:05 PM ET Jan 15, 2025.
- Stock to trade on split-adjusted basis on Nasdaq from Jan 16, 2025; CUSIP 019818202.
- No fractional shares; cash payment in lieu at closing price on Jan 15.
- Reverse split authorized by stockholders at special meeting on Jan 9, 2025 in connection with proposed merger with Kalaris Therapeutics.

## SEC filing metadata
- accession: 0001193125-25-004527
- form_type: 8-K
- ticker: KLRS
- cik: 0001754068
- company_name: Kalaris Therapeutics, Inc.
- filed_at: 2025-01-10T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.45
- calibrated_materiality_score: 0.45
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1754068/000119312525004527/0001193125-25-004527-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1754068/000119312525004527/d834173d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-004527
- JSON: https://secwatch.observer/filing/0001193125-25-004527.json
- Plain text: https://secwatch.observer/filing/0001193125-25-004527.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.